For Immediate Release
Irving, Tex. (July 21, 2004) – The Trustees of the American Respiratory
Care Foundation (ARCF) and INO Therapeutics are pleased to announce
the establishment of the INO Literary Award. The $50,000 endowment
is designed to recognize outstanding “First Author.”
Michael T. Amato, Trustee Chairman, says, “This endowment is a wonderful
addition to the Foundation’s line-up of respiratory therapy
awards. The Foundation, and most importantly the profession, is grateful
to INO Therapeutics for its support of respiratory therapy. This corporate
group and the Foundation’s other industry partners make everything
we do possible,” he adds.
INO Therapeutics is a global pharmaceutical company committed to
developing breakthrough therapies in the critical care areas of heart
and lung function. The company is focused on providing innovative
treatments to healthcare professionals and patients.
“We are excited to begin the creation of a closer working relationship
with American Association for Respiratory Care, and the endowment
is a great place to start,” states Gary Pyner, Director of Global
Marketing and Business Development for INO Therapeutics.
Amato says donors establish endowments with the ARCF to recognize
achievements made by individuals working in specific areas of research.
Endowments not only encourage further education and research in the
field of respiratory care, but also bring recognition to the named
donor supporting the respiratory profession.
If you would like more information about ARCF awards program, visit
our website.
The American Respiratory Care Foundation is dedicated to furthering
the art, science, quality, and technology of respiratory care. It
is a non-profit organization involved in supporting research, education,
and charitable purposes. Specific activities of the Foundation include
funding clinical and economic research, education activities, literary
awards and scholarly publications.
###